Compare COUR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | XNCR |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 2021 | 2013 |
| Metric | COUR | XNCR |
|---|---|---|
| Price | $5.85 | $12.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $11.07 | ★ $22.89 |
| AVG Volume (30 Days) | ★ 4.2M | 706.2K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.22 | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,500,000.00 | $125,576,000.00 |
| Revenue This Year | $9.34 | N/A |
| Revenue Next Year | $6.60 | $11.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.04 | ★ 13.65 |
| 52 Week Low | $5.47 | $6.92 |
| 52 Week High | $13.56 | $18.69 |
| Indicator | COUR | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 47.56 |
| Support Level | $5.47 | $10.92 |
| Resistance Level | $6.38 | $12.87 |
| Average True Range (ATR) | 0.27 | 0.71 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 7.91 | 49.37 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.